MeritValue

BIOREGENX, INC.

BRGXdata completeness 100%5 fiscal years on file
i. The business — what you’d actually own
FigureFY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$198,5841$42,1592$3.41M3$2.34M4$1.85M4
Net income−$96,8735−$78,3086−$3.6M7−$23.1M8−$1.54M8
Operating cash flow−$119,5179−$64,65210−$1.52M11−$324,14812$38,97212
Capital expenditure——$013$189,39014$9,05714
Free cash flow (derived)——−$1.52M11−$513,53812$29,91512
Total debt$400,00015$400,00016$400,00016$2.28M17$2.37M18
Cash & equivalents$24,35819$616,69620$125,40221$58,40421$69,38322
Diluted shares269.7M269.7M639.8M912.4M959.7M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
−$0.05
your share of equity
Profit it earned you last year
−$0.02
Free cash flow it threw off
$0
Debt you’d be carrying
$0.02

10 shares is a claim on −$0.05 of net worth that earned you −$0.02 and generated $0 of cash last year, against $0.02 of debt.

iii. Is this a good business?
Moat signal · return on equity
— avg · 5y

Not enough data in the filings for a return-on-capital reading.

seeing a moat in the numbers →
Management signal · capital allocation
+256% shares · 5y

Share count is up 256% over 5 years — owners have been diluted. Worth asking what they got for it. Total debt has risen 493% over the same window.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0
DCF · Growth Exit 10Y
not applicable
3y-median FCF non-positive — growth-exit DCF not applicable (see EPV)
DCF · Growth Exit 5Y
not applicable
3y-median FCF non-positive — growth-exit DCF not applicable (see EPV)
Earnings Power Value
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
Graham Number
not applicable
diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts
  1. 10-K · period ending 2021-12-31 · accession 0001683168-23-002125 (Revenues)
  2. 10-K · period ending 2022-12-31 · accession 0001683168-24-002317 (Revenues)
  3. 10-K/A · period ending 2023-12-31 · accession 0001683168-25-002623 (Revenues)
  4. 10-K · period ending 2024-12-31 · accession 0001683168-26-002975 (Revenues)
  5. 10-K · period ending 2021-12-31 · accession 0001683168-23-002125 (NetIncomeLoss)
  6. 10-K · period ending 2022-12-31 · accession 0001683168-24-002317 (NetIncomeLoss)
  7. 10-K/A · period ending 2023-12-31 · accession 0001683168-25-002623 (NetIncomeLoss)
  8. 10-K · period ending 2024-12-31 · accession 0001683168-26-002975 (NetIncomeLoss)
  9. 10-K · period ending 2021-12-31 · accession 0001683168-23-002125 (NetCashProvidedByUsedInOperatingActivities)
  10. 10-K · period ending 2022-12-31 · accession 0001683168-24-002317 (NetCashProvidedByUsedInOperatingActivities)
  11. 10-K/A · period ending 2023-12-31 · accession 0001683168-25-002623 (NetCashProvidedByUsedInOperatingActivities)
  12. 10-K · period ending 2024-12-31 · accession 0001683168-26-002975 (NetCashProvidedByUsedInOperatingActivities)
  13. 10-K/A · period ending 2023-12-31 · accession 0001683168-25-002623 (PaymentsToAcquirePropertyPlantAndEquipment)
  14. 10-K · period ending 2024-12-31 · accession 0001683168-26-002975 (PaymentsToAcquirePropertyPlantAndEquipment)
  15. 10-K · period ending 2021-12-31 · accession 0001683168-23-002125 (LongTermDebtNoncurrent)
  16. 10-K · period ending 2022-12-31 · accession 0001683168-24-002317 (LongTermDebtNoncurrent)
  17. 10-K/A · period ending 2024-12-31 · accession 0001683168-25-002623 (LongTermDebtNoncurrent)
  18. 10-K · period ending 2025-12-31 · accession 0001683168-26-002975 (LongTermDebtNoncurrent)
  19. 10-K · period ending 2021-12-31 · accession 0001683168-24-002317 (CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents)
  20. 10-K/A · period ending 2022-12-31 · accession 0001683168-25-002623 (CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents)
  21. 10-K/A · period ending 2023-12-31 · accession 0001683168-25-002623 (CashAndCashEquivalentsAtCarryingValue)
  22. 10-K · period ending 2025-12-31 · accession 0001683168-26-002975 (CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents)